Drug Database
LE

leucovorin + tegafur + uracil (leucovorin + UFT / UFT/leucovorin)

✓ Approved

Merck KGaA · TYMS · 小分子

什么是 leucovorin + tegafur + uracil?

leucovorin + tegafur + uracil 是一种小分子,由Merck KGaA研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Oral (PO)。

药物档案

商品名leucovorin + UFT, UFT/leucovorin
公司Merck KGaA
药物类别小分子
分子靶点TYMS
给药途径Injectable (Others), Intravenous (IV), Oral (PO)
状态Approved

作用机制

分子靶点

leucovorin + tegafur + uracil 作用于 1 个分子靶点:

TYMSthymidylate synthetase (DKCD, TMS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

leucovorin + tegafur + uracil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colorectal cancer✓ Approved

相关研究文献

PubMedBMC microbiology2026-11-16

Construction of an all-in-one doxycycline-inducible Cre/loxP marker recycling system in Aspergillus species.

Yakabe Shun S, Hamaguchi Ayuki A, Noguchi Masayuki M, Kakihara Kosuke K et al.

Aspergillus features numerous species with diverse characteristics, and efforts to identify the genes responsible for these traits are ongoing worldwide. Advanced multi-gene knockout technologies are required to analyze the functions of these genes. Although CRISPR/Cas9-based gene disruption methods have become widely used in many organisms, conventional homologous recombination remains the most reliable method for multiple-gene disruption in Aspergillus species. Here, we report the development of a novel marker recycling cassette for Aspergillus spp. This system enables highly efficient gene disruption and marker recycling by combining a doxycycline-inducible Cre/loxP system with a uracil biosynthesis pathway and counterselection using uracil analogs. Using the model filamentous fungi Aspergillus nidulans and the human pathogen Aspergillus fumigatus, we disrupted genes involved in conidial pigment biosynthesis and amino acid and vitamin biosynthesis. This system is expected to facilitate and accelerate functional genomic analyses in Aspergillus spp.

PMID 43035436
阅读全文 →
PubMedJournal of cancer research and clinical oncology2026-11-16

Profiling the tumor microenvironment of a hepatocellular carcinoma patient with primary resistance to immunotherapy plus anti-angiogenic therapy but exceptional response to chemotherapy plus bevacizumab.

Xu Qin Q, Zhu Rui R, Wang Zirui Z, Zhao Chengjian C et al.

Hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) carries a poor prognosis, and treatment options after failure of anti-angiogenic targeted agents combined with immune checkpoint inhibitor (ICI) remain limited. An adult patient with advanced HCC exhibited primary resistance to three sequential immunotherapy-based regimens: first-line lenvatinib plus camrelizumab (progressive lung metastases), second-line atezolizumab plus bevacizumab (rapid tumor marker surge), and third-line atezolizumab plus regorafenib (new liver and adrenal metastases within 3 months, suspicious for rapid disease progression following immunotherapy). Fortunately, fourth-line mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and fluorouracil) plus bevacizumab induced a partial response (PR) with significant tumor shrinkage and substantial declines in AFP and PIVKA-II. The case had shown a total progression-free survival (PFS) for more than 21 months until the latest follow-up in June 2026. Then, we performed 24-plex spatial tissue profiling of the primary tumor. The tumor microenvironment revealed three core features: immune-desert (lymphocytes < 5%, no tertiary lymphoid structures, exhausted PD-1 + CD8+ T cells), hyper-vascularization with disorganized endothelium and severe pericyte deficiency (αSMA coverage 2.9%), and high perivascular tumor proliferation. This unique "immune-desert, vessel-rich, rapidly proliferating" signature potentially accounts for the striking oxaliplatin-based chemotherapy sensitivity despite primary ICI-anti-angiogenic therapy resistance. This case suggests that in selected HCC patients with multiline ICI-anti-angiogenic therapy resistance, prompt transition to chemotherapy plus bevacizumab may yield profound responses.

PMID 43037761
阅读全文 →
PubMedThe Journal of chemical physics2026-11-16

Selective multilevel force fields for excited-state spectroscopy: A provenance-aware multi-provider workflow.

Barone Vincenzo V

Accurate electronic-structure methods for excited-state energies are increasingly accessible, but their application to geometries and vibrational properties is often limited because analytic energy derivatives are not available in most cases. Building on accuracy ladders established for ground-state structures and energetics, we extend the same hierarchical strategy to predominantly single-reference excited states, where analytic energy derivatives are often unavailable. The hierarchy combines a hybrid density-functional baseline (L0), a double-hybrid intermediate level (L1), equation-of-motion (EOM) coupled-cluster singles and doubles (L2), and a final L3 refinement by coupled-cluster singles, doubles, and approximate triples (CC3). An accurate composite scheme is obtained by combining L3 structures with L2 basis-set and core-valence increments, whereas harmonic force fields are obtained from L3 curvatures along L0 normal modes. Numerical derivatives are evaluated in parallel in symmetry-adapted, nonredundant internal coordinates; optimizations retain totally symmetric directions, and force fields retain symmetry-allowed blocks. Complete small-molecule force fields show that L3 curvatures along L0 normal modes reproduce the full L3 harmonic frequencies within 4 cm-1. HNO and HCF demonstrate that the complete-basis-set correction is state specific, whereas core-valence bond-length corrections can be transferred from the ground state. Across this demonstrative set, the resulting economical composite reduces the EOM/TZ baseline deviations from the CC3/TZ reference by more than 40% for all geometrical parameters; where the full CC3/TZ results are available, the economical composite outperforms both EOM/TZ alone and the ground-state-transfer construction used in prior strategies. A one-dimensional variational treatment describes the H2CO inversion; acrolein and tetrazine extend the construction to larger molecules, while the carbonyl subspace of uracil illustrates reduced-dimensionality L3 treatment.

PMID 43038149
阅读全文 →
PubMedJournal of medicinal chemistry2026-11-12

Discovery of C5-Substituted 2'-Fluorinated Pyrimidine Nucleosides as Potent and Orally Efficacious Anti-HSV Agents.

Li Ye Y, Zhang Wenbo W, Xue Shuwen S, Zhang Chaoran C et al.

Herpes simplex virus (HSV) infections remain a significant global health concern. Through phenotypic screening of a nucleoside-focused library followed by systematic structure-activity relationship (SAR) explorations, we identified C5-substituted 2'-fluorinated pyrimidine nucleosides as promising anti-HSV scaffolds. We found that introducing five-membered heteroaryls at the uracil C5 position significantly enhanced antiviral potency, whereas cytosine and alkynyl derivatives showed limited efficacy. The optimized lead, B10, exhibited potent in vitro inhibition against HSV-1 (EC50 = 0.60 μM) and HSV-2 (EC50 = 7.32 μM) with minimal cytotoxicity. Importantly, B10 demonstrated a highly favorable oral bioavailability of 48.0% in rats. In a murine intranasal HSV-1 infection model, oral administration of B10 significantly improved survival rates, alleviated weight loss, suppressed acute viral replication in the central nervous system, and reduced pulmonary viral titers. These findings highlight the 2'-fluoro-C5-heteroaryl uracil framework as a robust chemotype and establish B10 as an orally efficacious candidate for HSV therapy.

PMID 43018568
阅读全文 →
PubMedArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2026-11-12

Perioperative immunotherapy in resectable gastric adenocarcinoma: a critical review of current evidence.

Patino-Perez Valentina V, Castrillón-Arango Sarita S, Botello-Valencia Yensy Paola YP, Muñoz-Ruiz Edwin Oveimar EO et al.

Gastric cancer ranks fifth in global cancer incidence and fourth in mortality. In patients with gastric adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel, the FLOT regimen, constitutes the current therapeutic standard. Incorporating immune checkpoint inhibitors into perioperative schemes has emerged as a promising strategy, although its clinical and surgical impact requires critical appraisal in light of current evidence. To critically analyze contemporary scientific evidence on incorporating perioperative immunotherapy into resectable gastric adenocarcinoma management, evaluating its impact on oncologic outcomes, perioperative safety, and its role within current therapeutic algorithms. A critical narrative review through systematic searches in PubMed/MEDLINE, Embase, and Cochrane Library using relevant terms of the Medical Subject Headings (MeSH) thesaurus. The MATTERHORN trial demonstrated that the addition of durvalumab to FLOT significantly improves event-free survival (hazard ratio 0.71; 95%CI 0.58-0.86; p<0.001) and overall survival (hazard ratio 0.78; 95%CI 0.63-0.96; p=0.021), with a pathological complete response rate of 19.2% versus 7.2%, without increased surgical morbidity or mortality. The KEYNOTE-585 trial demonstrated improved pathological complete response with pembrolizumab, without significant overall survival benefit. Microsatellite instability-high, human epidermal growth factor receptor 2, and programmed death ligand 1 biomarkers are key determinants in therapeutic selection. Perioperative immune-related adverse events require specific surveillance. Adding durvalumab to FLOT establishes a new perioperative standard with level I evidence. Preoperative molecular characterization is key to decision-making. Integrating immunotherapy does not compromise the feasibility of gastrectomy with extended second-level lymphadenectomy, but requires specific expertise to manage immune-related toxicities. Durvalumab added to the fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen significantly improves event-free survival and overall survival, with pathological complete response, without increased surgical morbidity. The KEYNOTE-585 trial showed improved pathological complete response with pembrolizumab but failed to demonstrate overall survival benefit, confirming that immunotherapy efficacy is not uniform across agents or unselected populations. Preoperative molecular profiling of MSI-H, PD-L1, and HER2 status is now the central axis for individualized therapeutic decision-making in resectable gastric adenocarcinoma. Perioperative immunotherapy does not compromise the feasibility of gastrectomy with extended second-level lymphadenectomy but requires specific institutional expertise to manage immune-related adverse events. Gastric cancer continues to represent a significant oncologic burden worldwide, ranking fifth in incidence and fourth in mortality. Its high lethality is related to the frequent diagnosis at locally advanced stages and its aggressive biological behavior, particularly in high-risk regions such as East Asia and Latin America. In this context, radical gastrectomy with extended second-level lymphadenectomy constitutes the cornerstone of curative-intent treatment, providing adequate locoregional control and precise staging. Incorporating multimodal strategies, such as perioperative chemotherapy, has demonstrated improved oncologic outcomes compared with surgery alone. The associated immunotherapy based on immune checkpoint inhibitors has emerged as a promising strategy. The approval of durvalumab in combination with the fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen establishes a new perioperative standard with level I evidence, while the results of KEYNOTE-585 underscore that this benefit is neither uniform across agents nor applicable to unselected populations. Preoperative molecular characterization - particularly the determination of MSI-H, PD-L1, and HER2 - ceases to be a staging exercise to become the axis upon which the individual therapeutic strategy is constructed: it defines the systemic regimen, anticipates the probability of pathological complete response, and, in the MSI-H subgroup, opens the possibility of exploring - within the strict framework of research protocols - whether gastrectomy is necessary when treatment response is complete.

PMID 43017945
阅读全文 →
PubMedThe American journal of case reports2026-11-12

Fluorouracil-Associated Coronary Vasospasm and Reversible Cardiomyopathy Mimicking ST-Elevation Myocardial Infarction During a First Cycle of FOLFOX: A Case Report.

Alyacoub Ramez R, Veras Victoria Andy A

BACKGROUND 5-Fluorouracil (5-FU) is a mainstay chemotherapeutic agent for gastrointestinal malignancies but carries a recognized risk of cardiotoxicity, most often manifesting as coronary vasospasm that can mimic acute myocardial infarction. This report describes the case of a 50-year-old woman with ST-elevation myocardial infarction (STEMI) due to coronary artery vasospasm during continuous infusion of 5-FU as part of the first round of FOLinic acid (leucovorin), Fluorouracil (5-FU), and OXaliplatin (FOLFOX) chemotherapy for colorectal carcinoma. CASE REPORT A 50-year-old woman with colorectal carcinoma receiving her first cycle of FOLFOX developed severe chest pain during a continuous infusion of 5-FU. Initial emergency department evaluation was reportedly unremarkable, and she was discharged after symptomatic improvement with ketorolac. She returned emergently with recurrent crushing chest pain; a repeat electrocardiogram showed hyperacute T waves and ST-segment elevation, prompting ST-elevation myocardial infarction activation and transfer for emergent catheterization. Coronary angiography revealed no obstructive coronary artery disease. Echocardiography demonstrated a severely reduced left ventricular ejection fraction (LVEF) of 30% to 35% with apical akinesis, consistent with 5-FU-induced cardiomyopathy. 5-FU was permanently discontinued, and the patient was treated with vasodilator therapy, with complete resolution of symptoms and normalization of ventricular function on follow-up echocardiography. CONCLUSIONS 5-FU can precipitate life-threatening coronary vasospasm and a fully reversible cardiomyopathy even during a first chemotherapy cycle, in the absence of obstructive coronary artery disease. Early recognition, prompt drug interruption, and a multidisciplinary cardio-oncology approach, including an individualized decision between permanent discontinuation and carefully supervised rechallenge, are essential to guide safe oncologic decision-making.

PMID 43016114
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多leucovorin + tegafur + uracil